Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells

Biochemical and Biophysical Research Communications

Volumn 350, Issue 4, 2006, Pages 977-982

  Cigana, Cristina ^a   Nicolis, Elena ^a   Pasetto, Matteo ^a   Assael, Baroukh Maurice ^a   Melotti, Paola ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

AP 1; Azithromycin; Cystic fibrosis; IL 8; NF B

Indexed keywords

AZITHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; JOSAMYCIN; TRANSCRIPTION FACTOR AP 1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DNA BINDING; DRUG EFFECT; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; RESPIRATORY EPITHELIUM; TRANSCRIPTION INITIATION;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; AZITHROMYCIN; CELL LINE; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; INTERLEUKIN-8; NF-KAPPA B; TRANSCRIPTION FACTOR AP-1;

EID: 33750078400     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.09.132     Document Type: Article

References (41)

1. K.W. Southern, P.M. Barker, A. Solis, Cochrane Database Syst Rev. 2000;(3):CD002203. Macrolide antibiotics for cystic fibrosis. Child Health, University of Liverpool, Alder Hey Children's Hospital, Eaton Road, Liverpool, Merseyside, UK, L12 2AP.
2. Nalca Y., Jansch L., Bredenbruch F., Geffers R., Buer J., and Haussler S. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob. Agents Chemother. 50 (2006) 1680-1688
3. Wagner T., Soong G., Sokol S., Saiman L., and Prince A. Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest 128 (2005) 912-919
4. Tateda K., Ishii Y., Matsumoto T., Kobayashi T., Miyazaki S., and Yamaguchi K. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J. Infect. Chemother. 6 (2000) 1-7
5. Asgrimsson V., Gudjonsson T., Gudmundsson G.H., and Baldursson O. Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob. Agents Chemother. 50 (2006) 1805-1812
6. Pradal U., Delmarco A., Morganti M., Cipolli M., Mini E., and Cazzola G. Long-term azithromycin in cystic fibrosis: another possible mechanism of action?. J. Chemother. 17 (2005) 393-400
7. Venkatakrishnan A., Stecenko A.A., King G., Blackwell T.R., Brigham K.L., Christman J.W., and Blackwell T.S. Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am. J. Respir. Cell. Mol. Biol. 23 (2000) 396
8. Bonfield T.L., Panuska J.R., Konstan M.W., Hilliard K.A., Hilliard J.B., Ghnaim H., and Berger M. Inflammatory cytokines in cystic fibrosis lungs. Am. J. Respir. Crit. Care Med. 152 (1995) 2111
9. Osika E., Cavaillon J.M., Chadelat K., Boule M., Fitting C., Tournier G., and Clement A. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. Eur. Respir. J. 14 (1999) 339
10. van Heeckeren A., Ferkol T., and Tosi M. Effects of bronchopulmonary inflammation induced by Pseudomonas aeruginosa on adenovirus-mediated gene transfer to airway epithelial cells in mice. Gene Ther. 5 (1998) 345-351
11. Wolter J., Seeney S., Bell S., Bowler S., Masel P., and McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57 (2002) 212-216
12. Kawamura-Sato K., Iinuma Y., Hasegawa T., Horii T., Yamashino T., and Ohta M. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob. Agents Chemother. 44 (2000) 2869-2872
13. Culic O., Erakovic V., Cepelak I., Barisic K., Brajsa K., Ferencic Z., Galovic R., Glojnaric I., Manojlovic Z., Munic V., Novak-Mircetic R., Pavicic-Beljak V., Sucic M., Veljaca M., Zanic-Grubisic T., and Parnham M.J. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur. J. Pharmacol. 450 (2002) 277-289
14. Yamada T., Fujieda S., Mori S., Yamamoto H., and Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am. J. Rhinol. 14 (2000) 143-148
15. Tirouvanziam R., de Bentzmann S., Hubeau C., Hinnrasky J., Jacquot J., Péault B., and Puchelle E. Inflammation and infection in naive human cystic fibrosis airway grafts. Am. J. Respir. Cell. Mol. Biol. 23 (2000) 121-127
16. Carrabino S., Carpani D., Livraghi A., Di Cicco M., Costantini D., Copreni E., Colombo C., and Conese M. Dysregulated interleukin-8 secretion and NF-kappaB activity in human cystic fibrosis nasal epithelial cells. J. Cyst. Fibros. 5 (2006) 113-119
17. Pahl H.L. Activators and target genes of Rel/NF-B transcription factors. Oncogene 18 (1999) 6853-6866
18. Miller S.A., Selzman C.H., Shames B.D., Barton H.A., Johnson S.M., and Harken A.H. Chlamydia pnuemoniae activates NF-κB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation. J. Surg. Res. 90 (2000) 76-81
19. Rajan S., Cacalano G., Bryan R., Ratner A.J., Sontich C.U., van Heerckeren A., Davis P., and Prince A. Pseudomonas aeruginosa induction of apoptosis in respiratory epithelial cells: analysis of the effects of cystic fibrosis transmembrane conductance regulator dysfunction and bacterial virulence factors. Am. J. Respir. Cell. Mol. Biol. 23 (2000) 304-312
20. Di Paolo A., Barbara C., Chella A., Angeletti C.A., and Del Tacca M. Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. Pharmacol. Res. 46 (2002) 545-550
21. Vlahopoulos S., Boldogh I., Casola A., and Brasier A.R. Nuclear factor-kappaB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation. Blood 94 (1999) 1878-1889
22. Renard P., Ernest I., Houbion A., Art M., Le Calvez H., Raes M., and Remacle J. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res. 29 (2001) E21
23. Kawamura-Sato K., Iinuma Y., Hasegawa T., Horii T., Yamashino T., and Ohta M. Effect of subinhibitory concentrations of macrolides on expression of flagellinin Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob. Agents Chemother. 44 (2000) 2869-2872
24. Koehler D.R., Downey G.P., Sweezey N.B., Tanswell A.K., and Hu J. Lung inflammation as a therapeutic target in cystic fibrosis. Am. J. Respir. Cell. Mol. Biol. 31 (2004) 377-381
25. Hudson V.M. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic. Biol. Med. 30 (2001) 1440-1461
26. Amsden G.W. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. Antimicrob. Chemother. 55 (2005) 10-21
27. Tsai W.C., Rodriguez M.L., Young K.S., Deng J.C., Thannickal V.J., Tateda K., Hershenson M.B., and Standiford T.J. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am. J. Respir. Crit. Care Med. 170 (2004) 1331-1339
28. Li J., Johnson X.D., Iazvovskaia S., Tan A., Lin A., and Hershenson M.B. Signaling intermediates required for NF-kappa B activation and IL-8 expression in CF bronchial epithelial cells. Am. J. Physiol. Lung. Cell. Mol. Physiol. 284 (2003) L307-L315
29. DiMango E., Ratner A.J., Bryan R., Tabibi S., and Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J. Clin. Invest. 101 (1998) 2598-2606
30. Chan M.M., Chmura K., and Chan E.D. Increased NaCl-induced interleukin-8 production by human bronchial epithelial cells is enhanced by the DeltaF508/W1282X mutation of the cystic fibrosis transmembrane conductance regulator gene. Cytokine 33 (2006) 309-316
31. Mossman B.T., Lounsbury K.M., and Reddy S.P. Oxidants and signaling by mitogen-activated protein kinases in lung epithelium. Am. J. Respir. Cell. Mol. Biol. 34 (2006) 666-669
32. Rahman I., and MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur. Respir. J. 16 (2000) 534-554
33. Nicolis E., Pasetto M., Cigana C., Pradal U., Assael B.M., and Melotti P. The GCC repeat length in the 5′UTR of MRP1 gene is polymorphic: a functional characterization of its relevance for cystic fibrosis. BMC Med. Genet. 7 (2006) 7
34. Cigana C., Nicolis E., Assael B.M., and Melotti P. Reduction of tumor necrosis factor alpha (TNFα) expression by azithromycin (AZM) in CF airway epithelial cells. J. Cyst. Fibros. 5 (2006) S12
35. Ribeiro C.P., O'Neal W., Wu Y., Hurd H., and Boucher R.C. The macrolide azithromycin induces a proinflammatory response in human airway epithelia. Ped. Pulmonol. Suppl. 28 (2005) 238
36. Equi A., Balfour-Lynn I.M., Bush A., and Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 28 (2002) 978-984
37. Verleden G.M., Vanaudenaerde B.M., Dupont L.J., and Van Raemdonck D.E. Azithromycin reduces airway neutrophilia and IL-8 in patients with bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 174 (2006) 566-570
38. Williams T.J., and Verleden G.M. Azithromycin: a plea for multicenter randomized studies in lung transplantation. Am. J. Respir. Crit. Care Med. 172 (2005) 657-659
39. Shitrit D., Bendayan D., Gidon S., Saute M., Bakal I., and Kramer M.R. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J. Heart Lung Transplant. 24 (2005) 1440-1443
40. Verleden G.M., Dupont L.J., Vanhaecke J., Daenen W., and Van Raemdonck D.E. Effect of azithromycin on bronchiectasis and pulmonary function in a heart-lung transplant patient with severe chronic allograft dysfunction: a case report. J. Heart Lung Transplant. 24 (2005) 1155-1158
41. Karin M. Inflammation-activated protein kinases as targets for drug development. Proc. Am. Thorac. Soc. 2 (2005) 386-390